A phase IB open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with androgen deprivation therapy and other agents in subjects with castrate resistant prostate cancer (CRPC)

  • Parakh, Sagun (Primary Chief Investigator (PCI))

Project: Research

Project Details

Project Description

NMA Reference Number: HREC/17/MonH/92
Monash Health HREC Ref: RES-17-0000-163A
Effective start/end date4/04/193/04/24


  • clinical trial
  • phase 1 study
  • prostrate cancer
  • treatment efficacy